维普期刊资源整合服务平台（V6.5）

184篇 您的检索式：作者名="PICCART M"

选中清除导出查看参考文献查看引证文献引用追踪共10页首页上一页第1页下一页末页 /10 跳转

	题名	作者	年代	出处	被引量
1	An overview of HER2显示文摘	Piccart M	2001	Semin Oncol2001，28，618：	1
2	Long-term follow-up confirms a survival advantage of the paclitax-el-cisplatin regimen over the hamide-cispla-tin combination in advanced ovarian cancer显示文摘	Piccart M J Bertelsen K Stuart G	2003	Int J Gynecol Cancer2003，13，2：	1
3	Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results 显示文摘	Piccart M J Bertelsen K James K	2000	J Natl Cancer Inst2000，92，9：	1
4	Everolimus in postmenopausal hormone-receptor-positive advanced breast Cancer显示文摘	Baselga J Campone M Piccart M		0，，06：	1
5	A phase II study of docetaxel(Taxotere,DXT) in patients with advanced ovarian cancer relapsing 》12 months after their last platinum course显示文摘	Piccart MT Gore M Van Oosterom AT	1995	Pro Am Soc Clin Oncol1995，14，：	1
6	Everolimus inpostmenopausal hormone- receptor- positive advanced breast cancer显示文摘	Baselga J Campone M Piccart M	2012	N Engl J Med2012，366，6：	1
7	Everolimus in postmenopausal hormone receptor positive advanced breast cancer显示文摘	Baselga J Campone M Piccart M	2012	New England Journal of Medicine2012，366，6：	1
8	Long-term fallow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over thecy combination in advancedovarian cancer显示文摘	Piccart M J Bertelsen K Stuart G	2003	Int J Gynecol Cancer2003，13，2：	1
9	Everolim- us plus exemestane for hormone-receptor-positive, hu- man epidermal growth factor receptor-2-negative ad- vanced breast cancer: overall survival results from BO- LERO-2显示文摘	Piccart M Hortobagyi GN Campone M	2014	Ann Oncol2014，25，12：	1
10	Everolimus plus exemestane for hormone-receptor-positive,human epidermal growth factor receptor-2-negative advanced breast cancer:overall survival results from BOLERO-2?显示文摘	Piccart M Hortobagyi GN Campone M	2014	Ann Oncol2014，25，12：	1
11	An overview of HER2显示文摘	Lohrisch C Piccart M	2001	Semin Oncol2001，28，618：	1
12	Value of Ki67 in breast cancer:the debaie is still open 显示文摘	COLIZZA M SIDONI A PICCART GEBHART M	2010	Lancet Oncol2010，11，5：	1
13	Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer显示文摘	Baselga J Campone M Piccart M	2012	N Engl J Med2012，366，6：	1
14	HER2Jneu as a predictive factor in breast cancer显示文摘	Lohrisch C Piccart M	2001	Clin Breast Cancer:2001，2，2：	1
15	HER-2/neu as a predictive factor in breast cancer 显示文摘	Lohrisch C Piccart M	2001	Clin Breast Cancar2001，2，2：	1
16	Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer 显示文摘	BASELGA J CAMPONE M PICCART M	2012	New Eng J Med2012，366，6：	1
17	Identification andinterpretation of clinical and quality of life prognostic factors forsurvival and response to treatment in first-line chemotherapy inadvanced breast cancer显示文摘	Kramer JA Curran D Piccart M	2000	Eur J Cancer2000，36，12：	1
18	The third - generation non - steroidal aromatase inhibitors : a review of their clinical benefits in the second - line hormonal treatment of advanced breast cancer 显示文摘	Hamilton A piccart M	1999	Anals of Oncology1999，10，4：	1
19	The third-generation non-steroidal aromatase inhibitors : a review of their clinical benefits in the second-line hormomd treatment of advanced breast cancer 显示文摘	Hamilton A piccart M	1999	Ann Oncol1999，10，4：	1
20	Everolimus in postmeno- pausal hormone-receptor-positive advanced breast cancer 显示文摘	Baselga J Campone M Piccart M	2012	N Engl J Med2012，366，6：	1

返回顶部每页显示：

共10页首页上一页第1页下一页末页 /10 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示